Kim 2014a.

Methods	A review of the medical records of children and adolescents receiving MPH for ADHD between 2004 and 2011
Participants	Number of participants screened: not stated Number of participants included: 157 Number of participants followed up: 157 Number of withdrawals: 0 Diagnosis of ADHD: DSM‐IV (subtype: combined (71.3%), hyperactive‐impulsive (0.6%), inattentive (28.0%)) Age: mean 8.9, range 5‐14 years old IQ: 104.5 (SD 15.3), range 71‐143 Sex: 134 males, 23 females Methylphenidate‐naïve: none Ethnicity: not stated Country: Korea Comorbidity: ODD 30.6%, tic 17.8%, anxiety 11.5%, depressive disorder:4.5%, elimination disorder 2.5% Comedication: not stated Sociodemographics: not stated Inclusion criteria Between 5 and 14 years at the start of treatment DSM‐IV diagnosis of ADHD Receiving methylphenidate for ≥ 1 year A baseline weight and height z score > −2.0 relative to the general Korean population Exclusion criteria Prior exposure to a central nervous system stimulant or atomoxetine Having initiated MPH treatment before the age of 5 years IQ < 70 on the Korean Educational Developmental Institute's Wechsler Intelligence Scale for Children Past and/or current history of developmental disorder, including autism spectrum disorder Past and/or current history of schizophrenia, bipolar disorder, or other psychosis Current seizure disorder Mean compliance for the whole treatment period < 80% Taking an adjunct medication that could affect growth Past and/or current medical illness that could induce growth suppression
Interventions	Methylphenidate type: OROS‐MPH 52.2%, ER‐MPH 26.1%, combination 27.1% Mean methylphenidate dosage: 35.0 (SD 12.4 mg); 0.98 (SD 0.27) mg/kg/day Administration schedule: not stated Duration of intervention: ≥ 1 year; mean 28.8 months (SD 16.1); range 12‐88 months Treatment compliance: ≥ 80%
Outcomes	Non‐serious adverse events: Weight and height Z score measured during the first and second year of MPH treatment
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interests: funded by the Korean Ministry of Education, Science and Technology Key conclusions of the study authors: these results suggest that methylphenidate could be related to weight and height deficit in Korean children and adolescents, although the effects were minor, and disappeared after the 1st year Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no